血小板糖蛋白IIbIIIa受体拮抗剂在介入非介入患者中的应用

s RatioРPlaceboРIV GP IIb/IIIaР95% CIР*With/without heparin.?†Without heparin.?(l)=low dose.?(h)=high-dose.?Adapted from: Boersma E, et al. Lancet. 2002;359:189-198.РPlacebo BetterРGP IIb/IIIa BetterРOdds Ratio (95% CI)Р0.0Р1.0Р2.0РStudy (n)РGP IIb/IIIa Inhibitors in UA/NSTEMI: ?Death or MI at 30 DaysРFavors ControlРFavors TreatmentРYearРCAPTUREР1997РRESTOREР1998РEPISTENTР1999Р1997РCADILLAC-PР2002РADMIRALР2001РRAPPORTР1998РPetronioР2002РCADILLAC-SР2002Р0.01Р0.1Р1Р10Р100РStudyРERASERР1999РISAR-2Р2000РEPICРRisk Ratio and 95% CIРRR 0.79?Z=-2.27?2P=0.023РEPILOGР1999РESPRITР2002РOverallРTamburinoР2002РNР1265Р2141Р1603Р2099Р1046Р300Р483Р89Р1036Р225Р401Р2792Р2064Р15,651Р107РKarvouni E, et al. J Am Coll Cardiol. 2003;41:26-32.РIntravenous GP IIb/IIIa Receptor Antagonists Reduce Mortality after PCI